4,4,4-Trifluoro-N-[(1S)-1-{[(10S)-8-(2-hydroxyethyl)-9-oxo-6,8-diazatricyclo[9.4.0.0^{2,7}]pentadeca-1(15),2,4,6,11,13-hexaen-10-yl]carbamoyl}ethyl]butanamide is a complex, chiral organic compound featuring a fused tricyclic benzodiazepine core structure, a 2-hydroxyethyl substituent, and a terminal trifluorobutyl amide group. Its systematic name reflects this intricate architecture. This compound is a key intermediate in the synthesis of Sotorasib (AMG 510), a first-in-class, highly selective covalent inhibitor of the KRAS G12C mutant protein. KRAS G12C mutations are prevalent in several cancers, including non-small cell lung cancer (NSCLC), colorectal cancer, and pancreatic adenocarcinoma. As a critical synthetic precursor, this molecule is used to construct the final active pharmaceutical ingredient (API) that targets and irreversibly inhibits the oncogenic KRAS G12C protein, blocking its downstream signaling pathways. The development and production of this intermediate are crucial for the commercial manufacturing of Sotorasib, which received accelerated FDA approval for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic NSCLC. Its synthesis involves sophisticated chiral and amide bond-forming steps, highlighting its role as a high-value, non-generic pharmaceutical building block.